Form: PREM14C

Preliminary information statements relating to merger or acquisition

January 16, 2026

Documents

PREM14C EX-FILING FEES 0001894525 0-11 N/A 0001894525 1 2026-01-15 2026-01-15 0001894525 2026-01-15 2026-01-15 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

SC 14C

Apimeds Pharmaceuticals US, Inc.

Table 1 to Paragraph (a)(7)

                     
Line Item Type   Notes   Transaction
Valuation		   Fee Rate   Amount
of
Filing Fee
                     
Fees to be Paid   (1)   $  26,647,462.00   0.0001381   $  3,680.01
             
Total Transaction Valuation:   $ 26,647,462.00          
 Total Fees Due for Filing:             $ 3,680.01
 Total Fees Previously Paid:               0.00
 Total Fee Offsets:               0.00
 Net Fee Due:             $ 3,680.01

__________________________________________
Offering Note(s)

(1) Based on the 14,970,484 shares of APUS common stock outstanding at the closing of the Merger Agreement and the quoted market price of $1.78 per share, the total purchase consideration is $26,647,462.

The filing fee was calculated in accordance with 17 CFR ยง 240.0-11(c)(1) by multiplying the transaction valuation by the fee rate.